### Live Learner Notification

#### **Med Learning GroupA New Era of Treatment Opportunities for Small-Cell Lung Cancer in the Second Line: An Innovative 3D View**

**September 8, 2021**

**Online

Acknowledgement of Financial Commercial Support**

Jazz Pharmaceuticals Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 **Pharmacists and Pharmacy Technicians**

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-21-170-L04-P / JA4008163-9999-21-170-L04-T

**NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Discuss biological insights that drive the tumorigenesis of small-cell lung cancer.
2. Describe the clinical trials findings of combination regimens in the second-line treatment of patients with extensive-stage SCLC.
3. Apply NCCN clinical practice guidelines in the second-line management of patients with extensive-stage SCLC.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below:

|  |  |
| --- | --- |
| **Name** | **Relationship: Commercial Interest** |
| Stephen Liu | Consultant/Advisory Board: Amgen, AstraZeneca, Beigene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, Elevation Oncology, G1 Therapeutics, Genentech/Roche, Guardant Health, Inivata, Janssen, Jazz Pharmaceuticals, Lilly, Merck/MSD, Pfizer, PharmaMar, Regeneron, Takeda, Turning Point Therapeutics; Contracted Research (to institution): Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Erasca, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, Turning Point Therapeutics |
| Charu Aggarwal | Consultant/Advisory Board: AstraZeneca, Bristol-Myers Squibb, Celgene, EliLilly, Daichii, Bluprint, Merck, Roche |
| Felecia Beachum | NA |
| Matthew Frese | NA |
| Christina Gallo | NA |
| Daniel Dasilva | NA |
| Scott McGee-Plys | NA |
| Chris Drury | NA |
| Lauren Welch | NA |

**How to Get Your Certificate**

1. Go to <http://mlg.cmecertificateonline.com>

#### Click the**“9.8.21 A New Era of Treatment Opportunities for Small-Cell Lung Cancer in the Second Line: An Innovative 3D View**” link.

1. Evaluate the meeting, click the provided link to open your credit certificate.
2. Print/save all pages of your certificate for your records.

Questions? Email Certificate@AmedcoEmail.com